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Background: Pneumococcal conjugate vaccines (PCVs) generate herd protection by reducing nasopharyn-
geal (NP) carriage. Two PCVs, PCV10 and PCV13, have been in use for over a decade, yet there are few data
comparing their impact on carriage. Here we report their effect on carriage in a 2+1 schedule, compared
with each other and with unvaccinated controls.
Methods: Data from four groups within a parallel, open-label randomised controlled trial in Ho Chi Minh
City contribute to this article. Three groups were randomised to receive a 2+1 schedule of PCV10
(n = 250), a 2+1 schedule of PCV13 (n = 251), or two doses of PCV10 at 18 and 24 months (controls,
n = 197). An additional group (n = 199) was recruited at 18 months to serve as controls from 18 to
24 months. NP swabs collected at 2, 6, 9, 12, 18, and 24 months were analysed (blinded) for pneumococ-
cal carriage. This study aimed to determine if PCV10 and PCV13 have a differential effect on pneumococ-
cal carriage, a secondary outcome of the trial. We also describe the serotype distribution among
unvaccinated participants. Trial registration: ClinicalTrials.gov NCT01953510.
Findings: Compared with unvaccinated controls, a 2+1 schedule of PCV10 reduced PCV10-type carriage
by 45–62% from pre-booster through to 24 months of age, and a 2+1 schedule of PCV13 reduced
PCV13-type carriage by 36–49% at 12 and 18 months of age. Compared directly with each other, there
were few differences between the vaccines in their impact on carriage. Vaccine serotypes accounted
for the majority of carriage in unvaccinated participants.
Interpretation: Both PCV10 and PCV13 reduce the carriage of pneumococcal vaccine serotypes. The intro-
duction of either vaccine would have the potential to generate significant herd protection in this popu-
lation.
Funding: National Health and Medical Research Council of Australia, Bill & Melinda Gates Foundation.
 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Streptococcus pneumoniae (the pneumococcus) causes signifi-
cant morbidity and mortality in children under five years of age,
with pneumococcal pneumonia estimated to be responsible for
over 380,000 deaths among that age group in 2017 [1]. There arevaccine
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nes (PCVs) protect against a subset that most commonly cause
invasive pneumococcal disease. In addition to providing direct pro-
tection to the vaccinee, PCVs result in powerful herd protection by
reducing nasopharyngeal carriage and transmission of vaccine-
type pneumococci to unvaccinated individuals [2].
Two PCV formulations are licenced for paediatric use. Ten-
valent PCV (PCV10, Synflorix, GSK) includes serotypes 1, 4, 5,
6B, 7F, 9V, 14, 18C, 19F, and 23F. 13-valent PCV (PCV13, Prevenar,
Pfizer) includes the same serotypes, as well as 3, 6A, and 19A. A
third PCV, Pneumosil (10-valent: serotypes 1, 5, 6A, 6B, 7F, 9V,
14, 19A, 19F, and 23F) received World Health Organization
(WHO) pre-qualification in December 2019. Assessment of carriage
is essential to fully evaluate the benefits of vaccination, as carriage
is considered a prerequisite for disease and underpins herd protec-
tion [3,4]. However, despite the availability of both PCV10 and
PCV13 for over a decade, only one clinical trial has directly com-
pared the effect of these vaccines on pneumococcal carriage [5].
In Papua New Guinea, a setting with high pneumococcal carriage,
all participants received either PCV10 or PCV13 at 1, 2, and
3 months of age (with no unvaccinated control group), with car-
riage assessed at 4 and 9 months of age. Overall pneumococcal car-
riage transiently decreased in the PCV13 group compared with the
PCV10 group, but no differences in vaccine-type carriage were
observed. In Cyprus and Korea, PCV7-use was replaced with the
simultaneous use of both PCV10 and PCV13. Observational studies
in these two settings (among healthy children in Cyprus and
among children hospitalised with respiratory infections in Korea)
showed similar carriage rates with either vaccine, although a
non-significant 63% reduction in the carriage of additional PCV13
serotypes was noted among PCV13-recipients compared with
PCV10-recipients in Cyprus [6,7]. A review of several other obser-
vational studies reports that introduction of either PCV10 or
PCV13 leads to a reduction in vaccine-type carriage of a similar
magnitude among vaccinees for the serotypes included in the vac-
cine [8].
As there are limited data to guide vaccine formulation choice,
we undertook a randomised controlled trial of alternative PCV
schedules that included a comparison of PCV10 and PCV13 in a 2
+1 schedule (administered at 2, 4, and 9.5 months of age) in Ho
Chi Minh City, Vietnam. Previously, we found both vaccines were
safe and highly immunogenic [9]. Here, we aimed to determine if
vaccine formulation had a differential effect on nasopharyngeal
pneumococcal carriage and density in children during the first
two years of life, comparing PCV10-recipients, PCV13-recipients,
and unvaccinated controls. We also evaluate the most common
serotypes carried by unvaccinated participants over time, to
describe the serotypes circulating in the absence of vaccination.2. Methods
2.1. Study design and participants
Vietnam is a lower-middle income country in South-East Asia
with a population of over 95 million [10]. The burden of childhood
pneumonia mortality is high, and PCV is not currently included in
the national immunisation program [11]. We conducted an open
label randomised controlled trial (‘The Vietnam Pneumococcal Pro-
ject’), in districts 4 and 7 in Ho Chi Minh City, Vietnam. A detailed
protocol describing the trial aims, study design, study population,
and sample size has been published [12]. Infants were enrolled
at two months of age and randomised to one of six vaccination
schedules (Appendix Table S1), including a 2+1 PCV10 schedule
at 2, 4, and 9.5 months of age (group C), a 2+1 PCV13 schedule at
2, 4, and 9.5 months of age (group E), and a control group that2
received two doses of PCV10 at 18 and 24 months of age (group
F). Participants originally consented to be followed up to 18months
of age. Follow-up was later extended to 24 months of age, with an
additional group (group G) enrolled at 18 months of age to serve as
unvaccinated controls between 18 and 24 months. Group G partic-
ipants received a single dose of PCV10 at 24 months of age. Here
we describe the microbiological outcomes for participants who
received a 2+1 schedule of PCV10 (group C), a 2+1 schedule of
PCV13 (group E), and unvaccinated controls (groups F and G). Eth-
ical approval was obtained from the Human Research Ethics Com-
mittee of the Northern Territory Department of Health and
Menzies School of Health Research, Australia, and the Ministry of
Health Ethics Committee, Vietnam.
2.2. Randomisation and masking
As described previously, the allocation sequence for groups A–F
was generated using computerised block randomisation, stratified
by district [12]. Allocation concealment was maintained using
sealed envelopes with sequential study numbers on the outside
of the envelope. Group G participants were recruited at 18 months
of age from the study districts, concurrent with group A-F partici-
pants turning 18 months. The participants and study nurses were
not blinded to group allocation, as the trial arms had different vac-
cination schedules. All laboratory staff were blinded to group
allocation.
2.3. Study procedures and laboratory analyses
Study staff collected demographic information using data col-
lection forms. Demographic data were double-entered into an Epi-
Data v3.1 database, with validation checks completed before
upload into a Microsoft Access database. Laboratory data were
entered into a Microsoft Access (2–12 month time points) or Excel
(18 and 24 month time points) database.
Nasopharyngeal swabs were collected at 2, 6, 9, 12, 18, and
24 months of age, and stored and tested consistent with WHO
guidelines [13]. Samples collected at 2, 6, 9, and 12 months were
cultured on Columbia Colistin Naladixic Acid Horse Blood agar,
and S. pneumoniae identified based on colony morphology includ-
ing a-haemolysis and susceptibility to optochin [14]. Serotyping
was conducted on isolates using latex agglutination and Quellung
reaction with a complete set of antisera [15]. At 18 and 24 months
we performed a detailed assessment of the long-term effect of PCV
on pneumococcal carriage and density using molecular methods.
Samples were screened for pneumococci by quantitative real-
time PCR (qPCR) targeting the autolysin (lytA) gene [16]. Samples
with presumptive pneumococci were cultured on selective agar
before molecular serotyping by microarray (Senti-SP version 1.5,
BUGS Bioscience) [17]. Pneumococci were designated as non-
typeable if no serotype was identified using phenotypic testing,
or if microarray identified a non-encapsulated lineage (NT1, NT2,
NT3a, NT3b, NT4a, NT4b, NT2/NT3b). Samples were excluded from
all analyses if serotyping could not be conducted or a serotyping
result could not be determined.
2.4. Carriage outcomes
Vaccine-type carriage was defined as carriage of a serotype con-
tained in the vaccine formulation; PCV10-type carriage (1, 4, 5, 6B,
7F, 9V, 14, 18C, 19F, and 23F), or PCV13-type carriage (serotypes in
PCV10, and 3, 6A, and 19A). Non-vaccine-type carriage was defined
as carriage of a serotype not in the corresponding vaccine (exclud-
ing non-typeable pneumococci). Samples that contained both
vaccine-type and non-vaccine-type serotypes were considered
positive for both vaccine-type and non-vaccine-type carriage. Ser-
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known to interconvert [18], and ‘11F-like’ was reported as 11A
[19]. Serotype-specific density at 18 and 24 months was derived
by multiplying pneumococcal density (determined by lytA qPCR)
with the relative abundance of the serotype (determined by
microarray).
2.5. Statistical analyses
We determined the prevalence of overall pneumococcal,
PCV10-type, PCV13-type, serotype 3/6A/19A (additional PCV13-
type), non-PCV10-type, and non-PCV13-type carriage at 2, 6, 9,
12, 18, and 24 months for group C (2+1, PCV10), group E (2+1,
PCV13), and controls. The control group varied by timepoint and
was based on vaccination status: Group F (2–12 months), Groups
F and G combined (18 months), or Group G (24 months). We also
determined the overall probability of carriage, with participants
defined as carriers if they had a positive swab at any time point.
Carriage among PCV10-recipients (Group C), PCV13-recipients
(Group E), and controls who were recruited at 2 months of age
(Group F) was ascertained between 6 months of age (post-
primary series) and 18 months of age (the time of first PCV dose
in controls). Individual time point carriage prevalences and the
overall probability of carriage in each of the vaccine groups were
compared with controls, and a head-to-head comparison of
PCV10 and PCV13 was also conducted. Prevalence ratios (PR) and
95% confidence intervals (CI) were calculated, and groups were
compared using Fisher’s exact tests (5% level); one-sided when
vaccine groups were compared with controls, and two-sided when
vaccine groups were compared. Density data for pneumococcal
carriers were log10-transformed and reported as log10 genome
equivalents per ml (log10 GE per ml). As the transformed densityFig. 1. CONSORT diagram. Reasons withdrawn (n = 106): moved away and lost to follo
withdrawal (n = 16, 15%); and other (n = 4, 4%). Reasons excluded: no sample (either pa
n = 16); insufficient DNA for microarray (n = 24); pneumococcal carriage status could not
and excluded as a result of a protocol violation (PCV was administered outside the trial o
not consent to extension” completed the study at 18 months of age, as per the origin
PCV13 = 13-valent PCV.
3
data were not normally distributed, groups were compared using
the non-parametric Mann-Whitney U test. Statistical analyses
were conducted using Stata version 15.1 (StataCorp LLC). The trial
is registered at ClinicalTrials.gov, number NCT01953510.3. Role of the funding source
The funders of the study had no role in study design, data col-
lection, data analysis, data interpretation, or writing of the report.
The corresponding author had full access to all the data in the
study and had final responsibility for the decision to submit for
publication.4. Results
Between Sept 30, 2013, and Jan 9, 2015, 1201 two-month-old
infants were enrolled and randomised to groups A to F (Fig. 1).
Between Apr 14, 2015, and May 12, 2016, 199 18-month-old chil-
dren were recruited to the additional control group (group G). Par-
ticipants from groups C (2+1 PCV10, n = 250), E (2+1 PCV13,
n = 251), F (controls  18 months of age, n = 197), and G
(controls  18 months of age, n = 199) contribute data to this arti-
cle. The groups were balanced with respect to participant demo-
graphics at baseline and to most characteristics at 18 months of
age (Appendix Table S2). The exceptions were age at the 18 month
visit (18.3 months in group G, compared with 18.1 months in each
of groups C, E, and F, p < 0.001) and antibiotic use in the fortnight
prior to the 18 month visit (20.4% in group G, compared with 12.4%
in group C, 11.6% in group E, and 10.9% in group F, p = 0.020).
Of the 897 participants in this study, 106 were withdrawn and
12 did not consent to the extended follow-up beyond 18 monthsw-up (n = 67, 63%); refused a study procedure (n = 19, 18%); 16 (15%) voluntary
rticipants missed the study visit or attended the visit but had no sample collected,
be determined (n = 6); cultured isolate was irretrievable from freezer storage (n = 1);
r the sample was collected after administration of PCV, n = 3). Participants who ‘‘did
al study design. PCV = pneumococcal conjugate vaccine. PCV10 = ten-valent PCV.
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6 months, 95.6% (667/698) at 9 months, 93.4% (652/698) at
12 months, 92.9% (833/897) at 18 months, and 86.3% (594/688,
excluding group F and those that did not consent to the extension)
at 24 months. A total of 4103 swabs were collected, of which 4069
(99.2%) were included in the analyses. Of the 34 swabs not
included, 24 had insufficient DNA for microarray, pneumococcal
carriage status could not be determined in six, three were excluded
due to protocol violations, and one isolate was irretrievable from
freezer storage.
Overall, 616/4069 (15.1%) swabs contained capsular pneumo-
cocci. The majority of swabs (591/616, 95.9%) contained a single
serotype. Of the 25 instances of multiple serotype carriage, two
serotypes were identified in 23, and three serotypes were identi-
fied in each of the remaining two samples. In all, 30 different ser-
otypes were identified (Appendix Table S3). A total of 175 non-
typeable pneumococci were also identified, with two different
genetic lineages detected (NT2 and NT4b, determined at 18 and
24 months only).
We examined the prevalence of pneumococcal carriage over
time among PCV10-vaccinated participants, PCV13-vaccinated
participants, and controls. Participant characteristics at the time
of each swab were similar across groups (Table 1). The exceptions
were current antibiotic use at the 9 month visit (p = 0.047), age at
the 18 month visit (p = 0.016), and current symptoms of upper res-
piratory tract infection (URTI) at 24 months of age (p = 0.024).
Overall pneumococcal carriage was low at 2 months of age
among all three groups, ranging from 1.5-6.0% (Fig. 2, Table 2). Car-
riage increased steadily to 12 months of age in all groups, peaking
at 24.5% in controls and at 18.2% and 19.6% in the PCV10 and
PCV13 groups, respectively. At 18 months of age, overall pneumo-
coccal carriage was significantly lower in both vaccinated groupsTable 1
Characteristics of participants analysed, by time point.
Time point PCV10 group
Age, months 2 m 2.1 (1.9–2.4)
6 m 6.1 (5.7–6.9)
9 m 9.1 (9.0–10.1)
12 m 12.1 (12.0–14.0)
18 m 18.1 (17.9–20.9
24 m 24.1 (23.9–25.9
Any current breastfeeding 2 m 195/250 (78.0%)
6 m 129/243 (53.1%)
9 m 91/239 (38.1%)
12 m 71/231 (30.7%)
18 m 30/220y (13.6%)
24 m 9/205 (4.4%)
Presence of URTI symptoms 2 m 18/250 (7.2%)
6 m 43/243 (17.7%)
9 m 38/239 (15.9%)
12 m 50/231 (21.6%)
18 m 23/220y (10.5%)
24 m 31/205 (15.1%)
Antibiotic use in past fortnight 2 m 6/250 (2.4%)
6 m 21/243 (8.6%)
9 m 36/239 (15.1%)
12 m 25/231 (10.8%)
18 m 28/220y (12.7%)
24 m 18/205 (8.8%)
Current antibiotic use 2 m 3/250 (1.2%)
6 m 5/243 (2.1%)
9 m 10/239 (4.2%)
12 m 17/231 (7.4%)
18 m 13/220y (5.9%)
24 m 12/205 (5.9%)
Data are median (range) or n/N (%). p-values based on quantile regression with boo
comparisons of proportions). PCV = pneumococcal conjugate vaccine. PCV10 = ten-valen
runny nose and/or cough at the time of swab collection). *Data for controls comes fr
(24 months). yData missing for one participant.
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than controls, but this was not sustained out to 24 months of
age. PCV10-type carriage was reduced by 60% among PCV10-
recipients compared with controls at 9 months of age (prevalence
ratio (PR) 0.40 [95% CI 0.16–0.97] p = 0.029), and this continued
through to 24 months of age with reductions of 45–62% (Table 2).
PCV13-type carriage was reduced by 36% and 49% among PCV13-
recipients compared with controls at 12 and 18 months of age,
respectively (Table 2). For both vaccines, the most profound differ-
ences were seen at 18 months of age. There was a consistent trend
towards reduced carriage of the additional PCV13 serotypes (3, 6A,
and 19A) among PCV13-recipients compared with controls from
12 months of age onwards, with no such trend observed among
PCV10-recipients. In relation to non-vaccine-type carriage, non-
PCV10-type carriage appears higher among PCV10-recipients com-
pared with controls at 24 months of age, and non-PCV13-type car-
riage appears consistently higher among PCV13-recipients
compared with controls from 12 months of age onwards, although
these differences do not reach statistical significance.
The head-to-head comparison of PCV10 and PCV13 showed few
differences between vaccines (Fig. 2, Table 2). PCV10-type carriage
was consistently lower among PCV10-recipients than PCV13-
recipients from 9 months of age onwards (statistically significant
at 9 months of age). Among PCV13-recipients, serotype 3/6A/19A
carriage remained relatively constant over time, ranging from 3.0
to 3.8% between 6 and 24 months of age, and was generally lower
than among PCV10-recipients from 9 months of age onwards (sta-
tistically significant at 24 months of age). Serotype 6A carriage ran-
ged from 1.7 to 2.9%, serotype 19A carriage from 0.8 to 1.0%, and
there was only one occurrence of serotype 3 carriage (at 18 months
of age; Appendix Table S3). Serotype 3/6A/19A carriage fluctuated
more among PCV10-recipients, ranging from 2.7 to 9.8% between 6
and 24 months of age. Serotype 6A carriage ranged from 1.6 toPCV13 group Control group* p-value
2.1 (1.9–2.4) 2.1 (2.0–2.5) >0.999
6.1 (5.7–7.0) 6.1 (5.0–6.8) >0.999
9.1 (8.8–10.1) 9.1 (9.0–11.2) 0.117
12.1 (11.8–13.1) 12.1 (12.0–13.2) >0.999
) 18.1 (17.7–20.0) 18.2 (17.4–20.3) 0.018
) 24.1 (23.6–28.3) 24.1 (23.4–26.9) 0.321
194/250y (77.6%) 140/196y (71.4%) 0.208
117/239 (49.0%) 91/193 (47.2%) 0.437
88/235 (37.4%) 70/190 (36.8%) 0.966
62/230 (27.0%) 52/188 (27.7%) 0.637
28/218 (12.8%) 52/368 (14.1%) 0.908
13/200y (6.5%) 10/170 (5.9%) 0.636
14/251 (5.6%) 10/197 (5.1%) 0.603
37/239 (15.5%) 27/193 (14.0%) 0.564
51/235 (21.7%) 28/190 (14.7%) 0.118
44/230 (19.1%) 34/188 (18.1%) 0.635
35/218 (16.1%) 59/368 (16.0%) 0.134
44/200y (22.0%) 20/170 (11.8%) 0.024
12/251 (4.8%) 4/197 (2.0%) 0.178
21/239 (8.8%) 17/193 (8.8%) 0.994
41/235 (17.4%) 26/190 (13.7%) 0.551
20/230 (8.7%) 22/188 (11.7%) 0.575
25/218 (11.5%) 59/368 (16.0%) 0.255
18/200y (9.0%) 22/170 (12.9%) 0.337
6/251 (2.4%) 4/197 (2.0%) 0.602
9/239 (3.8%) 7/193 (3.6%) 0.684
18/235 (7.7%) 5/190 (2.6%) 0.047
14/230 (6.1%) 14/188 (7.4%) 0.820
13/218 (6.0%) 17/368 (4.6%) 0.709
9/200y (4.5%) 10/170 (5.9%) 0.788
tstrapped standard errors (for comparisons of medians) or chi-squared test (for
t PCV. PCV13 = 13-valent PCV. URTI = upper respiratory tract infection (presence of
om Group F (2–12 months), Groups F and G combined (18 months), or Group G
Fig. 2. Pneumococcal carriage prevalence over time. Prevalence (95% CI) of capsular, PCV10-type, PCV13-type, serotype 3/6A/19A, non-PCV10-type, and non-PCV13-type
carriage at 2, 6, 9, 12, 18, and 24 months of age, among participants who received a 2+1 schedule (at 2, 4, and 9.5 months of age) of PCV10, a 2+1 schedule of PCV13, or
unvaccinated controls. CI = confidence interval. PCV = pneumococcal conjugate vaccine. PCV10 = ten-valent PCV. PCV13 = 13-valent PCV. Control group data come from:
Group F (2–12 months); Groups F and G combined (18 months); or Group G (24 months).
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occurrences of serotype 3 carriage (all at 12 months of age; Appen-
dix Table S3).
In response to lower-than-anticipated pneumococcal carriage
rates we performed an additional analysis of the overall probability
of carriage at any time between 6 and 18 months of age (Appendix
Table S4). The overall probabilities of carriage generally reflect the
trends observed over time. PCV10- and PCV13-recipients were 34%
(95% CI 0–56%) and 29% (6 to 3%) less likely to be positive for
PCV10-type carriage at any time between 6 and 18 months than
controls, respectively, and were 24% (2 to 44%) and 27% (1–
46%) less likely to be positive for PCV13-type carriage (Appendix
Table S4). There were no differences in the overall probabilities
of carriage comparing PCV10 and PCV13-recipients.
Pneumococcal density was evaluated at 18 and 24 months of
age in pneumococcal carriers. Overall pneumococcal density was
similar at 18 and 24 months of age, with no differences between
PCV10-recipients, PCV13-recipients, and controls (Appendix Fig-
ure S1). Similarly, no differences were observed in PCV10-type,
PCV13-type, serotype 3/6A/19A, non-PCV10-type, or non-PCV13-
type carriage density in PCV10-recipients compared with PCV13-
recipients, or between either PCV group compared with the control
group.
We also examined the most common serotypes carried by
unvaccinated participants over time. Between 2 and 24 months
of age, a total of 22 capsular serotypes were identified among
unvaccinated participants, with the greatest diversity (15 different
serotypes) seen at 12 months of age. Over time, the most com-
monly carried serotypes were 6A, 6B, 19F, 23F, 19A, 23A, 15A,
and 14 (Fig. 3). These serotypes were responsible for 231 of the
266 (86.8%) pneumococci identified among unvaccinated partici-
pants. Across all time points, PCV10 serotypes accounted for
50.8% of pneumococci, and PCV13 serotypes for 75.6%.5
5. Discussion
PCV is included universally in the national immunisation sched-
ules of 136 countries [20]. PCV13 is used in three times as many
countries as PCV10, although the total number of recipients is sim-
ilar. In this paper we report the first head-to-head comparison of
the effect of PCV10 and PCV13 on pneumococcal carriage in a 2
+1 schedule. This schedule is becoming increasingly adopted by
countries, as the booster dose may increase the duration of protec-
tion and lead to greater herd effects [21]. We show that, compared
with unvaccinated controls, both vaccines reduced carriage of
pneumococcal serotypes included in the corresponding vaccine.
In the head-to-head comparison, PCV10 and PCV13 generally had
a similar impact on carriage.
At 9 months of age (prior to the booster dose), vaccination with
PCV10 resulted in a 60% reduction in PCV10-type carriage com-
pared with unvaccinated controls. This was sustained out to
24 months of age, with reductions of 45–62%. Vaccination with
PCV13 resulted in 32–49% reductions in PCV13-type carriage after
the booster dose (from 12 to 24 months of age). Interestingly, vac-
cination with PCV10 led to consistently lower levels of PCV10-type
carriage than vaccination with PCV13 from 9 months onwards,
although the differences were only statistically significant at
9 months of age.
Considering the serotypes unique to PCV13, vaccination with
PCV13 resulted in a consistent (albeit not statistically significant)
36–55% reduction in 3/6A/19A carriage compared with controls.
Such a trend was not observed with PCV10 vaccination, despite
our findings of modest immunogenicity to serotypes 6A and 19A
[9], two serotypes that are known to cross-react with serotypes
6B and 19F. In the head-to-head comparison of PCV10 and
PCV13, carriage of 3/6A/19A was 64% lower in the PCV13 group
than the PCV10 group at 24 months of age, driven primarily by ser-
Table 2
Pneumococcal carriage prevalence % (95% CI), prevalence ratio (95% CI), and Fisher’s exact p-value, by time point.
Carriage prevalence, % (95% CI) PCV10 vs controls PCV13 vs controls PCV13 vs PCV10
2+1 PCV10 2+1 PCV13 Controls* Prevalence ratio (95% CI) p-valuey Prevalence ratio (95% CI) p-valuey Prevalence ratio (95% CI) p-valuey
Any pneumococcal serotype carriage
2 m 3.6 (1.7–6.7) 6.0 (3.4–9.7) 1.5 (0.3–4.4) 2.36 (0.65–8.62) 0.146 3.92 (1.15–13.37) 0.013 1.66 (0.74–3.72) 0.296
6 m 11.9 (8.1–16.7) 11.7 (7.9–16.5) 10.9 (6.9–16.2) 1.10 (0.65–1.86) 0.426 1.08 (0.63–1.83) 0.454 0.98 (0.60–1.60) >0.999
9 m 14.2 (10.1–19.3) 14.9 (10.6–20.1) 16.3 (11.4–22.4) 0.87 (0.56–1.36) 0.320 0.91 (0.59–1.42) 0.393 1.05 (0.68–1.62) 0.897
12 m 18.2 (13.4–23.8) 19.6 (14.6–25.3) 24.5 (18.5–31.3) 0.74 (0.51–1.08) 0.074 0.80 (0.56–1.15) 0.138 1.08 (0.74–1.57) 0.722
18 m 15.4 (10.9–20.8) 17.4 (12.6–23.1) 23.9 (19.6–28.6) 0.64 (0.45–0.92) 0.008 0.73 (0.52–1.03) 0.040 1.13 (0.74–1.73) 0.607
24 m 21.0 (15.6–27.2) 19.4 (14.2–25.6) 21.2 (15.3–28.1) 0.99 (0.67–1.47) 0.531 0.92 (0.61–1.37) 0.384 0.93 (0.63–1.36) 0.712
PCV10-type carriage
2 m 1.2 (0.2–3.5) 2.8 (1.1–5.7) 0.0 (0.0–1.9) (..) 0.174 (..) 0.017 2.32 (0.61–8.89) 0.339
6 m 4.9 (2.6–8.5) 4.2 (2.0–7.6) 5.7 (2.9–10.0) 0.87 (0.39–1.92) 0.443 0.73 (0.32–1.69) 0.306 0.85 (0.37–1.92) 0.828
9 m 2.9 (1.2–5.9) 7.7 (4.6–11.8) 7.4 (4.1–12.1) 0.40 (0.16–0.97) 0.029 1.04 (0.53–2.04) 0.531 2.62 (1.11–6.14) 0.024
12 m 5.6 (3.0–9.4) 7.8 (4.7–12.1) 10.6 (6.6–16.0) 0.53 (0.27–1.04) 0.044 0.74 (0.40–1.35) 0.205 1.39 (0.70–2.77) 0.360
18 m 5.4 (2.8–9.3) 6.0 (3.2–10.0) 14.1 (10.7–18.1) 0.38 (0.21–0.70) 0.001 0.42 (0.24–0.76) 0.001 1.10 (0.51–2.35) 0.840
24 m 6.8 (3.8–11.2) 9.5 (5.8–14.4) 12.4 (7.8–18.3) 0.55 (0.29–1.05) 0.049 0.77 (0.43–1.37) 0.233 1.38 (0.71–2.68) 0.368
PCV13-type carriage
2 m 2.0 (0.7–4.6) 4.4 (2.2–7.7) 0.0 (0.0–1.9) (..) 0.054 (..) 0.002 2.19 (0.77–6.22) 0.203
6 m 8.2 (5.1–12.4) 7.9 (4.9–12.1) 8.8 (5.2–13.7) 0.93 (0.50–1.73) 0.481 0.90 (0.48–1.69) 0.440 0.97 (0.53–1.76) >0.999
9 m 8.8 (5.5–13.1) 10.6 (7.0–15.3) 11.6 (7.4–17.0) 0.76 (0.43–1.34) 0.213 0.92 (0.54–1.58) 0.438 1.21 (0.70–2.10) 0.537
12 m 13.0 (8.9–18.0) 11.3 (7.5–16.1) 17.6 (12.4–23.8) 0.74 (0.47–1.17) 0.123 0.64 (0.40–1.04) 0.046 0.87 (0.53–1.42) 0.669
18 m 8.1 (4.9–12.6) 9.6 (6.1–14.3) 19.0 (15.1–23.4) 0.43 (0.26–0.70) <0.001 0.51 (0.32–0.80) 0.001 1.18 (0.65–2.16) 0.618
24 m 16.1 (11.3–21.9) 12.4 (8.2–17.8) 18.2 (12.7–24.9) 0.88 (0.57–1.38) 0.340 0.68 (0.42–1.11) 0.080 0.77 (0.48–1.25) 0.322
3/6A/19A carriage
2 m 0.8 (0.1–2.9) 1.6 (0.4–4.0) 0.0 (0.0–1.9) (..) 0.312 (..) 0.097 1.99 (0.37–10.78) 0.686
6 m 3.3 (1.4–6.4) 3.8 (1.7–7.0) 3.1 (1.1–6.6) 1.06 (0.37–3.00) 0.569 1.21 (0.44–3.34) 0.461 1.14 (0.45–2.91) 0.810
9 m 5.9 (3.2–9.6) 3.0 (1.2–6.0) 4.2 (1.8–8.1) 1.39 (0.60–3.25) 0.294 0.71 (0.26–1.92) 0.335 0.51 (0.21–1.24) 0.180
12 m 7.4 (4.3–11.5) 3.5 (1.5–6.7) 7.4 (4.1–12.2) 0.99 (0.50–1.95) 0.559 0.47 (0.20–1.09) 0.056 0.47 (0.21–1.07) 0.098
18 m 2.7 (1.0–5.8) 3.7 (1.6–7.1) 5.7 (3.6–8.6) 0.48 (0.20–1.16) 0.066 0.64 (0.29–1.43) 0.184 1.35 (0.48–3.83) 0.599
24 m 9.8 (6.1–14.7) 3.5 (1.4–7.0) 6.5 (3.3–11.3) 1.51 (0.74–3.06) 0.168 0.54 (0.21–1.36) 0.137 0.36 (0.15–0.83) 0.016
Non-PCV10-type carriage
2 m 2.8 (1.1–5.7) 3.2 (1.4–6.2) 1.5 (0.3–4.4) 1.84 (0.48–7.02) 0.284 2.09 (0.56–7.79) 0.207 1.14 (0.42–3.09) >0.999
6 m 7.4 (4.4–11.5) 7.5 (4.5–11.6) 5.2 (2.5–9.3) 1.43 (0.68–3.03) 0.229 1.45 (0.69–3.08) 0.216 1.02 (0.54–1.91) >0.999
9 m 11.3 (7.6–16.0) 7.2 (4.3–11.3) 8.9 (5.3–13.9) 1.26 (0.71–2.25) 0.263 0.81 (0.42–1.54) 0.319 0.64 (0.36–1.14) 0.154
12 m 13.0 (8.9–18.0) 12.2 (8.2–17.1) 14.4 (9.7–20.2) 0.90 (0.56–1.47) 0.394 0.85 (0.52–1.39) 0.303 0.94 (0.58–1.52) 0.888
18 m 10.0 (6.3–14.7) 11.9 (7.9–17.0) 10.6 (7.6–14.2) 0.94 (0.57–1.54) 0.461 1.13 (0.71–1.80) 0.357 1.20 (0.70–2.05) 0.543
24 m 14.6 (10.1–20.2) 10.4 (6.6–15.5) 10.6 (6.4–16.2) 1.38 (0.80–2.39) 0.156 0.99 (0.54–1.79) 0.549 0.71 (0.42–1.20) 0.232
Non-PCV13-type carriage
2 m 2.0 (0.7–4.6) 1.6 (0.4–4.0) 1.5 (0.3–4.4) 1.31 (0.32–5.43) 0.498 1.05 (0.24–4.62) 0.631 0.80 (0.22–2.93) 0.751
6 m 4.1 (2.0–7.4) 3.8 (1.7–7.0) 2.1 (0.6–5.2) 1.99 (0.63–6.23) 0.177 1.82 (0.57–5.81) 0.232 0.92 (0.38–2.21) >0.999
9 m 5.4 (2.9–9.1) 4.3 (2.1–7.7) 4.7 (2.2–8.8) 1.15 (0.50–2.63) 0.460 0.90 (0.37–2.17) 0.496 0.78 (0.35–1.75) 0.670
12 m 5.6 (3.0–9.4) 8.7 (5.4–13.1) 6.9 (3.7–11.5) 0.81 (0.39–1.71) 0.365 1.26 (0.64–2.46) 0.314 1.55 (0.79–3.03) 0.212
18 m 7.2 (4.2–11.5) 8.3 (5.0–12.7) 4.9 (2.9–7.6) 1.48 (0.77–2.84) 0.158 1.69 (0.90–3.17) 0.073 1.14 (0.60–2.18) 0.724
24 m 5.4 (2.7–9.4) 7.0 (3.9–11.4) 5.3 (2.4–9.8) 1.01 (0.43–2.39) 0.581 1.32 (0.58–2.96) 0.329 1.30 (0.60–2.79) 0.541
Carriage determined by culture and latex agglutination/Quellung testing (2–12 months) and by DNA microarray (18–24 months). Samples that could not be serotyped are excluded. PCV = pneumococcal conjugate vaccine.
PCV10 = ten-valent PCV. PCV13 = 13-valent PCV. * Control data sourced from Group F (2–12 month time points), Group F and G combined (18 months), or Group G (24 months). yTwo-sided p-values were calculated for PCV10 vs















Fig. 3. Capsular pneumococcal carriage in unvaccinated participants. The top panel
shows the capsular pneumococcal carriage prevalence over time among unvacci-
nated participants. The bottom panel shows the proportion of carriage at each time
point attributable to each of the eight most commonly carried serotypes. Data come
from: all groups (2 months); Group F (2–12 months); Groups F and G combined
(18 months); or Group G (24 months).
B. Temple, M.L. Nation, V. T. T. Dai et al, Vaccine xxx (xxxx) xxxotype 6A. This is similar to the non-significant 63% reduction in
3/6A/19A observed among PCV13-recipients compared with
PCV10-recipients in Cyprus [6]. The long-term impact of a PCV10
schedule in Vietnam is unknown. Post-vaccine introduction data
from elsewhere on the impact of PCV10 on carriage of serotypes
6A and 19A vary. In Brazil, carriage of both 6A and 19A had not
changed three-years post-introduction of PCV10 [26], but by
seven-years 6A carriage had reduced and 19A carriage had
increased [27]. In Kenya, no effects were found on carriage of 6A
or 19A two-years post-introduction of PCV10 [22]. Six-years
post-introduction in Kenya there was still no effect on 6A carriage
but 19A carriage had increased [23], similar to findings 1½-2 years
post-introduction in Mozambique and three-years post-
introduction in Fiji [17,24] By contrast in Palestine, at three-years
post-introduction of PCV10 there was a decrease in 3/6A/19A car-
riage driven by 6A, with no change in 19A [25]. It may be that the
impact of PCV10 on serotypes 6A and 19A depends on the local
pneumococcal epidemiology. For serotype 3, for which PCV13 is
generally not considered to be effective, we observed only five
instances of carriage during the trial; it is therefore not possible
to determine whether PCV13 impacted serotype 3 carriage.
Serotype 19F is the most common cause of vaccine failure in
children [28], and has persisted in carriage in the wake of wide-
spread and long-term vaccination [29,30]. Our earlier immuno-
genicity analyses showed that PCV10 produced better antibody
and functional antibody responses to serotype 19F than PCV13 at
all time points [9]. Here we found no evidence of a differential
impact on 19F carriage between the two vaccines, and both
PCV10 and PCV13 appear to impact the carriage of 19F to a similar
degree as other vaccine types. However, the low serotype-specific
carriage rates (0.9% and 2.2% at 12 months of age, 1.8% and 1.8% at
18 months of age, and 1.5% and 2.0% at 24 months of age for 19F in
the PCV10 and PCV13 groups, respectively) and relatively short
follow-up time make it difficult to predict the long-term conse-
quences of our findings.7
In many settings, PCV introduction has resulted in serotype
replacement, whereby the reduction in vaccine-type carriage has
been offset by an increase in non-vaccine-type carriage. In Viet-
nam, where there is still no routine PCV use, we show no definitive
evidence of serotype replacement up to 24 months of age, although
the increase in non-PCV10-type carriage at 24 months of age
among PCV10 recipients and the trend towards higher non-
PCV13-type carriage among PCV13-recipients than controls from
12 months of age onwards suggest that post-introduction surveil-
lance for serotype replacement will be important. We did not
observe any differences in pneumococcal density between groups
at 18 or 24 months of age.
Data from unvaccinated participants provide information on
the serotypes circulating in the absence of pneumococcal vaccina-
tion. The majority (87%) of carriage was attributable to only eight
serotypes: vaccine-types 6B, 14, 19F, and 23F, additional PCV13-
types 6A and 19A, and non-vaccine-types 15A and 23A. PCV10
and PCV13 serotypes represent half and three-quarters of pneumo-
cocci carried. Although it is not known what level of carriage
impact is required to translate into herd protection effects, our
observed reductions in vaccine-type carriage combined with the
high representation of vaccine serotypes among unvaccinated par-
ticipants suggest that immunisation with either vaccine is likely to
impact the populations of pneumococci circulating in the
community.
This trial provided a rare opportunity to evaluate the impact of
vaccination with either PCV10 or PCV13 using an unvaccinated
comparator group. One limitation of the study design is the use
of different control groups at different time points, although few
differences in characteristics were observed between groups, sup-
porting the validity of this approach. Due to funding constraints we
were not able to perform DNA microarray for all time points. How-
ever, the same method was used for all groups at any given time
point. Lastly, we observed much lower pneumococcal carriage
rates than anticipated; some of the non-significant differences seen
between groups may therefore be due to a lack of power to detect
these differences.
In conclusion, we have shown that, compared with unvacci-
nated controls, 2+1 schedules of PCV10 and PCV13 each reduce
the carriage of pneumococcal vaccine serotypes, with the greatest
impact seen at 18 months of age. There was a trend towards PCV10
having a greater impact on PCV10-type carriage than PCV13, and a
trend towards PCV13 reducing serotype 3/6A/19A carriage that
was not seen with PCV10. The majority of pneumococci identified
from unvaccinated participants were vaccine-type, so the intro-
duction of either PCV10 or PCV13 would have the potential to gen-
erate significant herd protection in the population.
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